Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists

NCT07325435 on ClinicalTrials.gov · last registry update 2026-01-08

Closed to new participants; the 60 already enrolled are still being followed. Due to report 31 December 2027. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: MaryAnn Banerji
Sponsor type: Other
Enrollment: 60
Started: 2024-12-21
Primary completion: 2027-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Stimulated C-peptide Index during an Oral Glucose Tolerance Test is a measure of Beta Cell Function and will be measuresd at baseline and at 16 weeks after treatment with GLP-1 Receptor Agonist or SGLT2-Inhibitor

Conditions studied

Type 2 Diabetes (T2DM)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.